The Privatization of Peer Review: #BigPharma Would Benefit | Pharmaguy's Insights Into Drug Industry News |

With a tweet yesterday, an editor of Scientific Reports, one of Nature Publishing Group’s (NPG’s) open-access journals, has resigned in a very public protest of NPG’s recent decision to allow authors to pay money to expedite peer review of their submitted papers. “My objections are that it sets up a two-tiered system and instead of the best science being published in a timely fashion it will further shift the balance to well-funded labs and groups,” Mark Maslin, a biogeographer at University College London, tells ScienceInsider. “Academic Publishing is going through a revolution and we should expect some bumps along the way. This was just one that I felt I could not accept.”

The flap shines a light on a fledgling industry where several companies are now making millions of dollars by privatizing peer review. This niche is being exploited because journal peer review is usually a slow process. After all, it is typically an anonymous, volunteer effort for which scientists receive nothing more than thanks from journal editors and the good feeling of contributing to the scientific community. But for a price at some journals, authors now have the option of fast-tracking their submitted papers through an accelerated peer-review process.